Physician profile
Marina Ryan
NPI 1487165163
$2,932.59
in general payments reported to CMS, 2019-2025
16 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $453 · 2023: $447 · 2024: $782 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.88 | 2021-2025 | Wegovy |
| Gilead Sciences, INC. | $361.33 | 2023-2025 | Biktarvy, Epclusa |
| Neurocrine Biosciences, INC. | $252.20 | 2024-2025 | Ingrezza |
| Abbvie INC. | $228.95 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $208.25 | 2022-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $187.77 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $141.24 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $124.99 | 2023 | Arexvy |
| Sanofi-Aventis U.S. LLC | $124.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Amgen INC. | $124.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $117.77 | 2023 | Quviviq |
| Insmed, INC. | $114.64 | 2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $97.23 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $88.51 | 2024 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.